文献速递垂体与肾上腺疾病

绝经对泌乳素瘤演变有有益影响:99例患者研究

Menopause Has a Beneficial Influence on the Evolution of Prolactinomas. A Study of 99 Patients.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

这项回顾性研究分析了99例在DA治疗期间经历绝经的泌乳素瘤女性,发现绝经后继续稳定剂量DA者中位泌乳素从18.0 µg/L降至24个月时7.9 µg/L,56例成功停药者中41例(73%)在中位29个月随访中维持缓解,15例(27%)复发且多在停药第一年内。

要点

  • 绝经后继续稳定剂量DA的泌乳素瘤女性,中位泌乳素从18.0 µg/L降至24个月时7.9 µg/L。
  • 56例符合严格停药标准者中41例(73%)在中位29个月随访中维持缓解。
  • 复发15例(27%),多在停药第一年内;停药后3-6个月泌乳素是唯一独立预测因素。

核心结论

  • 绝经对泌乳素瘤演变有有益影响;符合严格停药标准时,三分之二绝经后女性可预期持续缓解,复发通常轻微且无症状。

研究设计与样本

  • 回顾性研究,纳入两家三级学术医院99例在DA治疗泌乳素瘤期间经历绝经的女性,诊断时平均年龄37.9±8.1岁,微腺瘤67例、大腺瘤32例(其中侵袭性12例)。

主要发现

  • 绝经后继续稳定剂量DA者,中位泌乳素从绝经前18.0 µg/L降至绝经后3-6个月9.8 µg/L(n=71,P=.05),24个月降至7.9 µg/L(n=45,P<.001)。
  • 冠状面面积在24个月时从16.5 mm²显著降至8.2 mm²(n=34,P<.01)。
  • 56例成功停用DA且均符合严格停药标准,41例(73%)在中位29个月随访中维持缓解。
  • 15例(27%)复发,多数在停药后第一年内;停药后3-6个月测定的泌乳素浓度是复发的唯一独立预测因素。
  • 23例接受雌激素-孕激素替代治疗,未影响泌乳素瘤结局。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Menopause is thought to have beneficial effects in women with prolactinoma, potentially offering a higher chance for successful dopamine agonist (DA) withdrawal. However, strong evidence supporting this remains limited. OBJECTIVE: To assess the impact of menopause on prolactinoma evolution and recurrence after DA withdrawal. DESIGN: Retrospective study. SETTING: Two tertiary academic hospitals. PATIENTS: We retrospectively analyzed data from 99 women undergoing menopause (Mp, defined as 12 months of amenorrhea, low estradiol, and FSH > 25 U/L) while still on DA treatment for a prolactinoma (mean age at diagnosis: 37.9 ± 8.1 years). The tumors were microadenomas in 67 cases and macroadenomas in 32 (12 invasive). RESULTS: In postmenopausal women continuing DA at stable doses, median prolactin levels decreased significantly from 18.0 µg/L before Mp to 9.8 µg/L 3 to 6 months after Mp (n = 71, P = .05) and to 7.9 µg/L after 24 months (n = 45, P < .001). Coronal surface also decreased significantly from 16.5 to 8.2 mm² at 24 months (n = 34, P < .01). DA treatment was successfully discontinued in 56 women, all meeting stringent criteria for discontinuation, with 41 (73%) remaining in remission over a median follow-up of 29 months. Recurrence occurred in 15 women (27%), mostly within the first year after DA withdrawal. Prolactin concentration measured 3 to 6 months after DA discontinuation was the only independent predictor of recurrence. Estrogen-progestin replacement therapy, given in 23 women, did not influence prolactinoma outcome. CONCLUSION: We confirm that menopause has a beneficial effect on the evolution of prolactinomas. When fulfilling stringent criteria for DA withdrawal, two-thirds of postmenopausal women can expect sustained remission, and recurrences are generally mild and asymptomatic.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Constantinescu SM, Nava CM, Chasseloup F, et al. Menopause Has a Beneficial Influence on the Evolution of Prolactinomas. A Study of 99 Patients. J Clin Endocrinol Metab. 2025. PMID: 40052439. doi:10.1210/clinem/dgaf152

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。